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The potentially tridentate ligand 2-pyridinecarbaldehyde isonicotinoyl hydrazone (HPCIH) and its
analogues are an emerging class of orally effective Fe chelators that show great promise for the
treatment of Fe overload diseases. Herein, we present an extensive study of the Fe coordination
chemistry of the HPCIH analogues including the first crystallographically characterised FeII complex of
these chelators. Unlike most other clinically effective Fe chelators, the HPCIH analogues bind FeII and
not FeIII. In fact, these chelators form low-spin bis-ligand FeII complexes, although NMR suggests that
the complexes are close to the high-spin/low-spin crossover. All the Fe complexes show a high potential
FeIII/II redox couple (> 500 mV vs. NHE) and cyclic voltammetry in aqueous or mixed aqueous/organic
solvents is irreversible as a consequence of a rapid hydration reaction that occurs upon oxidation. A
number of the HPCIH analogues show high activity at inducing Fe efflux from cells and also at
preventing Fe uptake by cells from the serum Fe transport protein transferrin. As a class of ligands,
these chelators are more effective at reducing Fe uptake from transferrin than inducing Fe mobilisation
from cells. This may be related to their ability to intercept FeII after its release from transferrin within
the cell. Our studies indicate that their Fe chelation efficacy is due, at least in part, to the fact that these
ligands and their FeII complexes are neutral at physiological pH (7.4) and sufficiently lipophilic to
permeate cell membranes.
Introduction
Under normal circumstances in mammals, only trace levels of
Fe exist outside its physiological sinks i.e. transferrin, ferritin,
heme, iron–sulfur clusters etc., where it is constantly shuttled
between storage and reuse.1,2 Excess Fe, particularly when it is
uncomplexed, can catalyse the generation of harmful reactive
oxygen species (ROS) through Fenton chemistry.3 Thus, cellular
Fe homeostasis is a crucial function. Humans are especially
susceptible to Fe overload as they have no natural mechanism for
Fe excretion.4,5 Irrespective of the cause ofFeoverload (e.g. chronic
blood transfusions in the treatment of b-thalassemia, Friedreich’s
ataxia etc.), the ROS that ensue from Fe-mediated redox reactions
damage membranes, proteins and DNA, leading to pathology.1
Sufferers of Fe overload must then undergo chelation therapy to
facilitate Fe excretion.1
For many years, the only Fe-chelating drug that was approved
and widely utilised world-wide for the treatment of Fe overload
was desferrioxamine B (DFO or desferal), a tri-hydroxamic acid
which possesses high specificity for FeIII (Fig. 1).1
Unfortunately, the use of DFO suffers from serious problems,
including: (i) its high cost, making it unaffordable for patients in
developing countries, where the incidence of b-thalassemia major
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Fig. 1 Biologically active Fe chelators.
is greatest, (ii) it is poorly absorbed via the oral route6 and does
not readily access intracellular pools due to its hydrophilicity;7
and (iii) DFO is rapidly metabolised, necessitating prolonged
subcutaneous infusions (12–24 h day−1, 5–6 times week−1) leading
to poor compliance.1,8 DFO is also ineffective at mobilising
Fe from Fe-loaded mitochondria,9–11 rendering it unsuitable for
the treatment of the neuro- and cardio-degenerative disease,
Friedreich’s ataxia.
Deferiprone (1,2-dimethyl-3-hydroxypyridin-4-one), also
known as L1 (Fig. 1), is moderately effective as an orally-active
Fe chelator.1 However, the clinical use of deferiprone has a
controversial history and is still not approved world-wide.12
Recently, the chelator ICL670A (deferasirox or Exjade, Fig. 1)
has been approved for clinical use in Europe, USA, Canada and
Australia as an orally-active Fe chelator. ICL670A is the most
promising and advanced alternative to DFO that may be given
either as an oral suspension or in capsule form.13,14 Another
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potentially orally-active chelator, deferitrin (Fig. 1), has recently
completed a Phase I human trial.15
Our interest is in the development of chelators based on 2-
pyridinecarbaldehyde isonicotinoyl hydrazone (HPCIH, Fig. 2)
that show high Fe chelation efficacy in cell culture models
and are orally effective in mice.16–18 All analogues bear the
2-pyridinecarbaldehyde hydrazone backbone, which comprises
pyridine-N, imine-N and carbonyl-O donor atoms forming a
meridionally coordinating tridentate ligand (Fig. 2). A number
of HPCIH analogues have been synthesized to create a series
with varying physicochemical properties, such as lipophilicity and
ionisation constants.16,19 Given the high activity that someHPCIH
analogues have shown in vitro11,16 and in vivo,18 an investigation of
their physicochemical properties and Fe coordination chemistry is
clearly warranted.
Fig. 2 The HPCIH analogues and the related hydrazone HPKIH.
Previously, we showed that the parent compound of the series,
HPCIH, was oxidised in aerated aqueous solution in the pres-
ence of Fe to afford N-(isonicotinoyl)-N ′-(picolinoyl)hydrazine
(H2IPH, Fig. 1).20 Interestingly, other closely related ligands of this
series (e.g. 2-pyridinecarbaldehyde (4′-aminobenzoyl)hydrazone;
HPCAH) did not undergo oxidation in the presence of Fe(II) or
Fe(III), suggesting it was a reaction unique to HPCIH.19 However,
isolation and characterisation of FeII complexes from the HPCIH
series has been challenging, in contrast to the facile isolation and
crystallographic characterisation of a number of other divalent
first row transition metal complexes of HPCIH and HPC4AH
(Mn, Co, Ni, Cu and Zn).19
Here we report the first comprehensive investigation of the
HPCIH analogues and their FeII complexes. Moreover, we have
synthesized a number of novel HPCIH chelators which are
isomeric with other chelators from this family that have demon-
strated activity in the past (e.g. HPCNH, HPCPH, HPC2BBH,
HPC3BBH, Fig. 2). From these studies, we define important
structure–activity relationships of the HPCIH analogues that
should be noted for the design of future chelators for clinical
use.
Experimental
Syntheses
All commercially available chemicals and solvents used in this
work were of analytical grade. DesferalTM (DFO) was from
Novartis, Summit, NJ, USA.
Free ligands
The hydrazones were prepared via Schiff base condensation.16,19
Recrystallisation from aqueous EtOH afforded pure ligand in
>80% yield. Spectroscopic data for HPCIH and HPC4AH
(formerly referred to as HPCAH) have been reported19 and only
results for the new ligands are included below. Slow evaporation of
aqueous methanol (1 : 1) solutions of the ligands afforded crystals
suitable for X-ray work.
The hydrogen perchlorate salts [H2PC3BBH]ClO4·2H2O and
[H2PC4BBH]ClO4·H2O were crystallised from aqueous solutions
acidified to pH 2 with HClO4. The crystals that formed were
suitable for X-ray work and these were filtered off and air dried.
2-Pyridinecarbaldehyde nicotinoyl hydrazone (HPCNH·2H2O).
Anal. found C, 55.04 H, 5.43; N, 21.35%; calculated for
C12H14N4O3: C, 54.96; H, 5.38; N, 21.36%. IR: m˜CO 1662 cm−1.
1H NMR (DMSO-d6): d = 7.43 (t, 1H), 7.58 (q, 1H), 7.94 (m,
2H), 8.22 (d, 1H), 8.48 (s, 1H), 8.62 (d, 1H), 8.78 (d, 1H), 9.10
(d, 1H) and 12.23 (s, 1H). 1H NMR (methanol-d4): d = 7.46 (t,
1H), 7.62 (q, 1H), 7.91 (t, 1H), 8.27 (d, 1H), 8.38 (d, 1H), 8.43
(s, 1H), 8.59 (d, 1H), 8.78 (d, 1H) and 9.14 (d, 1H). 13C NMR
(DMSO-d6): d = 120.3, 123.9, 124.8, 129.2, 135.8, 137.2, 148.9,
149.8, 152.7, 153.2 and 162.2. 13C NMR (methanol-d4): d = 122.4,
125.3, 126.2, 130.3, 137.6, 138.6, 149.6, 150.1, 150.2, 153 4, 154.2
and 164.9 ppm.
2-Pyridinecarbaldehyde picolinoyl hydrazone (HPCPH). Anal.
found C, 63.82; H, 4.39; N, 24.93%; calculated for C12H10N4O: C,
63.71; H, 4.46; N, 24.76%. IR: m˜CO 1698 cm−1. 1H NMR (DMSO-
d6): d = 7.41 (m, 1H), 7.67 (m, 1H), 7.90 (t, 1H), 8.10 (m, 3H), 8.62
(d, 2H), 8.70 (s, 1H) and 12.51 (s, 1H). 1H NMR (methanol-d4):
d = 7.48 (t, 1H), 7.66 (t, 1H), 8.00(m, 3H), 8.28 (m, 2H), 8.56 (s,
1H), 8.61 (d, 1H) and 8.75 (d, 1H). 13C NMR (DMSO-d6): d =
120.3, 123.1, 124.7, 127.4, 137.1, 138.3, 148.8, 149.6, 149.7, 153.6
and 161.1. 13CNMR (methanol-d4): d = 122.4, 124.1, 126.1, 128.4,
138.6, 138.9, 150.0, 150.2, 150.4, 154.5 and 163.7 ppm.
2-Pyridinecarbaldehyde benzoyl hydrazone (HPCBH·H2O).
Anal. found C, 64.00; H, 5.31; N, 17.08%; calculated for
C13H13N3O2: C, 64.19; H, 5.39; N, 17.29%. IR: m˜CO 1658 cm−1.
1H NMR (DMSO-d6): d = 7.53 (m, 4H), 7.92 (m, 4H), 8.50 (s,
1H), 8.61 (d, 1H) and 12.09 (s, 1H). 1H NMR (methanol-d4): d =
7.56 (m, 4H), 7.96 (m, 3H), 8.32 (d, 1H), 8.44 (s, 1H) and 8.60 (d,
1H). 13C NMR (DMSO-d6): d = 120.1, 124.6, 128.0, 128.8, 132.2,
133.4, 137.1, 148.3, 149.8, 153.5 and 163.7. 13C NMR (methanol-
d4): d = 122.3, 126.0, 128.9, 129.8, 133.6, 133.8, 138.6, 149.4, 150.2,
154.5 and 167.3 ppm.
2-Pyridinecarbaldehyde-3′-aminobenzoyl hydrazone (HPC3AH).
Anal. found C, 65.14; H, 5.13; N, 23.18%; calculated for
C13H12N4O: C, 64.99; H, 5.03; N, 23.32%. IR: m˜CO 1661 cm−1. 1H
NMR (DMSO-d6): d = 5.39 (s, 2H), 6.77 (d, 1H), 7.12 (m, 3H),
7.39 (t, 1H), 7.90 (m, 2H), 8.47 (s, 1H), 8.61 (d, 1H) and 11.94 (s,
This journal is © The Royal Society of Chemistry 2007 Dalton Trans., 2007, 3232–3244 | 3233
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1H). 13C NMR (DMSO-d6): d = 113.2, 114.9, 117.4, 120.0, 124.5,
129.2, 134.3, 137.1, 147.8, 149.2, 149.8, 153.7 and 164.4 ppm.
2-Pyridinecarbaldehyde-4′-bromobenzoyl hydrazone (HPC-
4BBH·H2O). Anal. found C, 48.72; H, 3.62; N, 13.10%;
calculated for C13H12BrN3O2: C, 48.47; H, 3.75; N, 13.04%. IR:
m˜CO 1666 cm−1. 1H NMR (DMSO-d6): d = 7.38 (t, 1H), 7.85
(m, 6H), 8.47 (s, 1H), 8.59 (d, 1H) and 12.20 (s, 1H). 1H NMR
(methanol-d4): d = 7.48 (t, 1H), 7.73 (d, 2H), 7.94 (m, 3H), 8.34
(d, 1H), 8.43 (s, 1H) and 8.63 (d, 1H). 13C NMR (DMSO-d6): d =
120.2, 124.7, 126.0, 130.1, 131.8, 132.4, 137.1, 148.6, 149.7, 153.4
and 162.7 ppm.
2-Pyridinecarbaldehyde-3′-bromobenzoyl hydrazone (HPC-
3BBH·H2O). Anal. found C, 48.74; H, 3.60; N, 13.05%;
calculated for C13H12BrN3O2: C, 48.47; H, 3.75; N, 13.04%. IR:m˜CO
1662 cm−1. 1H NMR (DMSO-d6): d = 7.41 (t, 1H), 7.50 (t, 1H),
7.80 (d, 1H), 7.88 (t, 1H), 7.92 (d, 1H), 7.98 (d, 1H), 8.10 (s, 1H),
8.46 (s, 1H) and 8.61 (d, 1H). 13C NMR (DMSO-d6): d = 120.0,
121.8, 124.5, 127.0, 130.2, 130.8, 134.7, 135.3, 136.9, 148.6, 149.6,
153.1 and 161.9 ppm.
2-Pyridinecarbaldehyde-2′-bromobenzoyl hydrazone (HPC-
2BBH). Anal. found C, 51.72; H, 3.36; N, 14.20%; calculated for
C13H10BrN3O: C, 51.34; H, 3.31; N, 13.82%. IR: m˜CO 1671 cm−1.
1H NMR (DMSO-d6): d = 7.44 (m, 4H), 7.73 (t, 1H), 7.93 (m,
2H), 8.31 (s, 1H), 8.60 (m, 1H) and 12.15 (s, 1H). 1H NMR
(methanol-d4): d = 7.47 (m, 4H), 7.60 (d, 1H), 7.92 (t, 1H), 8.24
(s, 1H), 8.29 (d, 1H) and 8.58 (d, 1H). 13C NMR (DMSOd6): d =
120.5, 122.6, 126.6, 129.3, 130.5, 133.5, 134.3, 137.1, 139.0, 149.7,
150.6, 153.2 and 166.3 ppm.
2-Pyridinecarbaldehyde-4′-hydroxybenzoyl hydrazone (HPC-
4HH). Anal. found C, 64.64; H, 4.61; N, 17.52%; calculated for
C13H11N3O2: C, 64.72; H, 4.60; N, 17.42%. IR: m˜CO 1648 cm−1. 1H
NMR (DMSO-d6): d = 6.88 (d, 2H), 7.39 (m, 1H), 7.83 (d, 2H),
7.92 (t, 2H), 8.45 (s, 1H), 8.60 (d, 1H), 10.19 (s, 1H) and 11.86
(s, 1H). 1H NMR (methanol-d4): d = 6.95 (d, 2H), 7.46 (t, 1H),
7.93 (m, 3H), 8.33 (d, 1H), 8.41 (s, 1H) and 8.59 (d, 1H). 13CNMR
(DMSO-d6): d = 115.3, 120.0, 123.8, 124.4, 130.1 (br), 137.0, 147.3
(br), 149.7, 153.7, 161.1 and 163.2 (br). 13C NMR (methanol-d4):
d = 116.4, 122.2, 124.3, 125.9, 131.1, 138.6, 148.4, 150.1, 154.7
and 163.1 ppm.
2-Pyridinecarbaldehyde-3′-hydroxybenzoyl hydrazone (HPC-
3HH). Anal. found C, 64.61; H, 4.60; N, 17.20%; calculated for
C13H11N3O2: C, 64.72; H, 4.60; N, 17.42%. IR: m˜CO 1662 cm−1. 1H
NMR (DMSO-d6): d = 7.01 (m, 1H), 7.38 (m, 4H), 7.90 (m, 2H),
8.49 (s, 1H), 8.60 (d, 1H), 9.82 (s, 1H) and 12.01 (s, 1H). 13C NMR
(DMSO-d6): d = 114.8, 118.5, 119.2, 120.1, 124.6, 129.8, 134.8,
137.1, 148.2, 149.7, 153.6, 157.7 and 163.7 ppm.
2-Pyridinecarbaldehyde-2′-thienyl hydrazone (HPCTH·H2O).
Anal. found C, 52.84; H, 4.36; N, 16.87%; calculated for
C11H11N3O2S: C, 53.00; H, 4.45; N, 16.86%. IR: m˜CO 1632 cm−1.
1H NMR (DMSO-d6): d = 7.24 (t, 1H), 7.42 (m, 1H), 7.95 (br, m,
5H), 8.63 (d, 1H) and 12.06 (s, 1H). 13C NMR (DMSO-d6): d =
120.3, 124.6, 127.1 (br), 128.4 (br), 129.6 (br), 132.5 (br), 132.9
(br), 135.3 (br), 137.2, 138.1 (br), 144.7 (br), 147.9 (br), 149.8,
153.3, 158.1 (br) and 161.8 (br) ppm.
2-Pyridinecarbaldehyde-2′-furoyl hydrazone (HPCFH·H2O).
Anal. found C, 56.69; H, 4.76; N, 17.91%; calculated for
C11H11N3O3: C, 56.65; H, 4.75; N, 18.02%. IR: m˜CO 1661 cm−1.
1H NMR (methanol-d4): d = 6.69 (q, 1H), 7.38 (d, 1H), 7.44 (t,
1H), 7.80 (d, 1H), 7.93 (t, 1H), 8.28 (d, 1H), 8.43 (s, 1H) and 8.58
(d, 1H). 13C NMR (methanol-d4): d = 113.3, 117.6, 122.2, 126.0,
138.6, 147.4, 147.5, 149.5, 150.1, 154.4 and 157.6 ppm.
Fe complexes (general synthesis)
The free ligand (4 mmol) was dissolved in 40 cm3 of MeCN and
32 mmol of triethylamine and the mixture purged with nitrogen.
Then 1.6 mmol of Fe(ClO4)2·6H2O was dissolved in 10 cm3 of
oxygen-free MeCN and added drop-wise to the basic ligand solu-
tion with stirring under nitrogen. The mixture was subsequently
refluxed under nitrogen for 3 h. The green FeII complexwas filtered
off, while the mixture was hot and washed with methanol and
acetone. The products were usually of high purity and no re-
crystallisation was necessary unless stated. Yields: 75–95%.
[Fe(PCIH)2]·1/2H2O. Anal. found: C, 55.42; H, 3.44; N,
21.79%; calculated for C24H19FeN8O2.5: C, 55.94; H, 3.72; N,
21.74%. IR: m˜max (most intense peak) 1362 cm−1. Electronic
spectrum (MeOH): kmax, nm (e, dm3 mol−1 cm−1) 649 (4000), 349
(39 000), 268 (19 500), 229 (35 200). 1H NMR (d6-DMSO): d =
10.33 (s, 2H), 10.79 (s, 2H), 13.69 (s, 1H), 15.09 (s, 1H), 19.75 (s,
1H) ppm.
Fe(PCNH)2. Anal. found: C, 56.94; H, 3.59; N, 22.27%;
calculated for C24H18FeN8O2: C, 56.93; H, 3.58; N, 22.13%. IR:
m˜max (most intense peak) 1363 cm−1. Electronic spectrum (MeOH):
kmax, nm (e, dm3 mol−1 cm−1) 642 (3190), 348 (32 900), 270 sh
(∼ 18 000), 240 (26 800). 1H NMR (d6-DMSO): d = 9.60 (s, 1H),
9.74 (s, 1H), 10.65 (s, 1H), 11.86 (s, 1H), 13.86 (s, 1H), 15.61 (s,
1H), 20.31 (s, 1H) ppm.
[Fe(PCBH)2]·1/2H2O. Anal. found: C, 60.90; H, 3.90; N,
16.36%; calculated for C26H21FeN6O2.5: C, 60.83; H, 4.12; N,
16.37%. IR: m˜max (most intense peak) 1358 cm−1. Electronic
spectrum (MeOH): kmax, nm (e, dm3 mol−1 cm−1) 637 (3170), 348
(30 500), 256 (22 700). 1H NMR (d6-DMSO): d = 8.38 (s, 1H),
9.25 (s, 2H), 9.80 (s, 2H), 12.03 (s, 1H), 13.77 (s, 1H), 16.62 (s, 1H)
ppm.
[Fe(PC4AH)2]·21/2H2O. Anal. found: C, 54.08; H, 4.26; N,
19.34%; calculated for C26H27FeN8O4.5: C, 53.90; H, 4.26; N,
19.34%. IR: m˜max (most intense peak) 1363 cm−1. Electronic
spectrum (MeOH): kmax, nm (e, dm3 mol−1 cm−1). 633 (2180), 381
(33 500), 332 (32 800). 1H NMR (d6-DMSO): d = 6.65 (s, 2H),
8.64 (s, 2H), 9.63 (s, 1H), 11.80 (s, 1H), 13.90 (s, 1H), 15.78 (s, 1H)
ppm.
Fe(PC3AH)2. Anal. found: C, 58.06; H, 4.08; N, 20.71%;
calculated for C26H22FeN8O2: C, 58.44; H, 4.15; N, 20.97%. IR:
m˜max (most intense peak) 1359 cm−1. Electronic spectrum (MeOH):
kmax, nm (e, dm3 mol−1 cm−1) 637 (2440), 351 (27 800), 296 (27 300),
236 (40700). 1H NMR (d6-DMSO): d = 6.07 (s, 2H), 7.72 (s, 1H),
8.20 (s, 3H), 10.88 (s, 1H), 12.11 (s, 1H), 13.52 (s, 1H) ppm.
Fe(PC4BBH)2. Anal. found: C, 47.19; H, 2.47; N, 12.87%;
calculated for C26H18Br2FeN6O2: C, 47.16; H, 2.74; N, 12.69%.
IR: m˜max (most intense peak) 1361 cm−1. Electronic spectrum
3234 | Dalton Trans., 2007, 3232–3244 This journal is © The Royal Society of Chemistry 2007
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(MeOH): kmax, nm (e, dm3 mol−1 cm−1) 640 (2620), 351 (34 800),
268 (28 300). 1H NMR (d6-DMSO): d = 10.11 (s, 2H), 10.31 (s,
2H), 13.06 (s, 1H), 14.70 (s, 1H), 18.26 (s, 1H) ppm.
[Fe(PC3BBH)2]·1/2H2O. Anal. found: C, 46.18; H, 2.64; N,
12.53%; calculated for C26H19Br2FeN6O2.5: C, 46.53; H, 2.85;
N, 12.52%. IR: m˜max (most intense peak) 1361 cm−1. Electronic
spectrum (MeOH): kmax, nm (e, dm3 mol−1 cm−1) 641 (2410), 349
(28 000), 260 sh (∼ 21 000). 1H NMR (d6-DMSO): d = 9.04 (s,
1H), 9.79 (s, 1H), 10.28 (s, 1H), 10.42 (s, 1H), 13.33 (s, 1H), 15.03
(s, 1H), 19.18 (s, 1H) ppm.
[Fe(PC2BBH)2]·1/2EtOAc. The precipitate from the reaction
mixture was re-crystallised from ethyl acetate, which afforded dark
green crystals suitable for X-ray work. Anal. found: C, 47.50; H,
3.05; N, 11.67%; calculated for C28H22Br2FeN6O3: C, 47.62; H,
3.14; N, 11.90%. IR: m˜max (most intense peak) 1377 cm−1. 1H NMR
(DMSO-d6): d = 1.16 (t, 3H), 1.99 (s, 3H), 4.03 (q, 2H), 7.58 (br, t,
3H), 8.78 (br, d, 6H), 9.48 (br, s, 2H), 11.25 (br, s, 2H), 12.15 (br, s,
3H) and 14.71 (br, s, 2H) ppm. Electronic spectrum (MeOH): kmax,
nm (e, dm3 mol−1 cm−1) 624 (1580), 337 (19 300), 294 (26 000). 1H
NMR (d6-DMSO): d = 8.21 (s), 9.55 (s), 10.35 (s), 12.18 (s), 13.33
(s), 16.37 (s) ppm.
[Fe(PC4HH)2]·1/2H2O. Anal. found: C, 57.27; H, 3.95; N,
15.11%; calculated for C26H21FeN6O4.5: C, 57.26; H, 3.88; N,
15.41%. IR: m˜max (most intense peak) 1368 cm−1. Electronic
spectrum (MeOH): kmax, nm (e, dm3 mol−1 cm−1) 634 (2230), 363
(31 600), 307 (28 300), 241 (20300). 1HNMR (d6-DMSO): d = 9.66
(s, 2H), 10.55 (s, 2H), 11.66 (s, 1H), 12.73 (s, 1H), 14.64 (s, 1H),
16.99 (s, 1H) ppm.
[Fe(PC3HH)2]·1/2H2O. Anal. found: C, 57.02; H, 3.61; N,
15.24%; calculated for C26H21FeN6O4.5: C, 57.26; H, 3.88; N,
15.41%. IR: m˜max (most intense peak) 1369 cm−1. Electronic
spectrum (MeOH): kmax, nm (e, dm3 mol−1 cm−1) 637 (3160), 353
(33 300), 260 (24 400). 1HNMR (d6-DMSO): d = 8.55 (s, 1H), 9.68
and 9.78 (d, 3H in total), 10.96 (s, 1H), 12.11 (s, 1H), 13.59 (s, 1H),
15.80 (s, 1H) ppm.
[Fe(PCTH)2]·1/2H2O. Anal. found: C, 49.87; H, 3.17; N,
15.85%; calculated for C22H17FeN6O2.5S2: C, 50.30; H, 3.26; N,
16.00%. IR: m˜max (most intense peak) 1371 cm−1. Electronic
spectrum (MeOH): kmax, nm (e, dm3 mol−1 cm−1) 635 (2090), 360
(35 500), 316 (22 800), 268 (21200). 1H NMR (d6-DMSO): d =
10.20 (s, 1H), 10.64 (s, 1H), 11.39 (s, 1H), 16.02 (s, 1H), 18.05 (s,
1H), 24.72 (s, 1H) ppm.
[Fe(PCFH)2]·H2O. Anal. found: C, 53.04; H, 3.21; N, 16.96%;
calculated for C22H18FeN6O5: C, 52.61; H, 3.61; N, 16.73%. IR:
m˜max (most intense peak) 1386 cm−1. Electronic spectrum (MeOH):
kmax, nm (e, dm3 mol−1 cm−1) 632 (1950), 357 (32 500), 327 (24 100),
311 (23 800), 243 (16 400). 1H NMR (d6-DMSO): d = 9.07 (s, 1H),
9.25 (s, 1H), 10.30 (s, 1H), 14.08 (s, 1H), 15.51 (s, 1H), 20.29 (s,
1H) ppm.
Physical methods
Instrumentation
Solution UV/visible spectra were measured on a Perkin-Elmer
Lambda 40 spectrophotometer. Infrared spectra were measured
on a Perkin-Elmer Model 1600 FT-IR spectrophotometer with
compounds being dispersed as KBr discs. 1HNMR and 13CNMR
spectrawere obtainedwithBrukerAC200F (200MHz) andAV400
(400 MHz) instruments with TMS as internal standard for free
ligand spectra or as an external standard contained within a
capillary for 1H NMR spectra of all FeII complexes.
Cyclic voltammetry was performed with a BAS100B/W po-
tentiostat employing a glassy carbon or platinum working
electrode and a platinum auxiliary electrode. For non-aqueous
electrochemical experiments in MeCN, a Ag/AgNO3 (0.01 M in
MeCN) reference electrode was used. Potentials for non-aqueous
electrochemistry are cited versus the ferrocene/ferrocenium (Fc+/0)
couple. For voltammetry in 1 : 1 DMF : H2O solution or in water,
an aqueous Ag/AgCl reference electrode was employed (E◦ =
196mV vs. NHE). Concentrations of complexes were 1–5mMand
0.1 M Et4NClO4 was the supporting electrolyte for non-aqueous
solvent systems or 0.1 M NaClO4 for aqueous media.
Potentiometric titrations
Potentiometric titrations were performed with a Metrohm Titro-
processor under a nitrogen atmosphere in a water-jacketed cham-
ber at 298 K as described.19 The titrant was 0.1 M Et4NOH,
standardised with HCl. Data were refined by a non-linear least-
squares refinement method using the program SuperQuad.21
Crystallography
Cell constants at 293 K were determined by a least-squares fit to
the setting parameters of 25 independent reflections measured
on an Enraf-Nonius CAD4 four-circle diffractometer employ-
ing graphite-monochromated Mo-Ka radiation (0.71073 A˚) and
operating in the x-2h scan mode within the range 2 < 2h <
50 A˚. The data set collected at 150 K employed an Oxford
Cryosystems Cryostream Cooler (600 Series). Data reduction and
empirical absorption corrections (w-scans) were performed with
the WINGX suite of programs.22 Structures were solved by direct
methods with SHELXS and refined by full-matrix least-squares
analysis with SHELXL-97.23 All non-H atoms were refined with
anisotropic thermal parameters, except C3B and C6B in the
structure of [Fe(PC2BBH)2]·1/2EtOAc where the data could only
support partial anisotropic refinement due to the large number of
parameters (two formula units in the asymmetric unit). Aryl and
aminoH-atomswere included at estimated positions using a riding
model. Water and amide H-atoms (if any) were first located from
difference maps then constrained at these positions in a similar
manner to that employed for the remaining H-atoms. Molecular
structure diagrams were produced with ORTEP3.24 Crystal data
are summarised in Table 1.
Biological methods
Materials
Chelators were dissolved in DMSO as 10 mmol dm−3 stock
solutions and diluted in medium containing 10% foetal calf serum
(Commonwealth Serum Laboratories, Melbourne, Australia) so
that the final [DMSO] < 0.5% (v/v).25 Human SK-N-MC
neuroepithelioma cells were from the American Type Culture
Collection (Rockville, Maryland, USA) and cultured by standard
procedures.26 This latter cell type was used as the effects of
chelators on its Fe metabolism are well characterised.16,25,27
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Table 1 Crystallographic data
HPCNH·2H2O HPCPH HPC2BBH·2H2O HPC3HH
[H2PC3BBH]
·ClO4·2H2O
[H2PC4BBH]
·ClO4·H2O
[FeII(PC2BBH)2]·
1/2CH3COOC2H5
Formula C12H14N4O3 C12H10N4O C13H14BrN3O3 C13H11N3O2 C13H15BrClN3O7 C13H13BrClN3O6 C28H22Br2FeN6O3
Molecular wt 262.27 226.24 340.18 241.25 440.64 422.62 706.14
Crystal system Triclinic Monoclinic Trigonal Monoclinic Monoclinic Orthorhombic Triclinic
a/A˚ 6.420(1) 8.469(1) 26.311(3) 4.618(1) 6.839(5) 10.434(1) 13.833(3)
b/A˚ 8.001(1) 13.836(2) 22.759(3) 16.527(5) 10.7200(6) 14.191(3)
c/A˚ 12.943(2) 9.806(2) 11.270(1) 10.663(3) 15.507(5) 14.691(2) 16.863(2)
a/◦ 87.76(2) 69.80(1)
b/◦ 76.47(2) 105.64(1) 96.98(2) 90.079(5) 89.23(1)
c /◦ 80.73(1) 64.05(2)
V/A˚3 637.9(2) 1106.5(3) 6757(1) 1112.4(4) 1752.7(15) 1643.2(3) 2756.0(9)
T/K 293 293 293 293 293 293 150
Z 2 4 18 4 4 4 4
Space group P1¯ P21/n R3¯ P21/c P21/c Pc21na P1¯
l/mm−1 0.101 0.092 2.748 0.101 2.538 2.699 3.489
Indep. refs (Rint) 2247 (0.0117) 1941 (0.0262) 2639 (0.0801) 1964 (0.0559) 3082 (0.0264) 1699 (0.0366) 9682 (0.0906)
R1 (obs. data) 0.0341 0.0400 0.0477 0.0494 0.0405 0.0386 0.0811
wR2 (all data) 0.1017 0.1236 0.1179 0.1589 0.1157 0.0833 0.2568
a Variant of Pna21.
59Fe2–transferrin labelling
Radioactive 59Fe (as ferric chloride in 0.1 M HCl) was purchased
fromDupont (NENProducts, Boston,Massachusetts, USA). Hu-
man apotransferrin (Sigma) was prepared and labelled with 59Fe
to produce 59Fe-transferrin (59Fe-Tf) using established methods.26
Iron efflux and uptake experiments
The effect of the HPCIH chelators on the release of 59Fe from
SK-N-MC cells pre-labelled with 59Fe-Tf and their ability to
prevent 59Fe uptake from 59Fe-Tf were determined using standard
procedures.25,27,28 Briefly, efflux of 59Fe from cells was examined
after a 3 h preincubation of cells at 37 ◦C with 59Fe-Tf ([Tf] =
0.75 lmol dm−3; [Fe]= 1.5 lmol dm−3). The cells were thenwashed
four times with ice-cold phosphate buffered saline (PBS) followed
by a 3 h reincubation at 37 ◦C in the presence of medium alone
(control) or each of the chelators at 25 lmol dm−3. The overlying
medium was then removed and placed in c-counting tubes. The
cells were removed from the culture dish in 1 cm3 of PBS using a
plastic spatula and added to separate c-counting tubes.
Internalised 59Fe uptake from 59Fe-Tf by SK-N-MC neuroep-
ithelioma cells was examined in the presence of the chelators. Cells
were incubated for 3 h at 37 ◦Cwith 59Fe-Tf ([Tf]= 0.75lmol dm−3;
[Fe] = 1.5 lmol dm−3) in the presence and absence of chelators
(25 lmol dm−3). The cells were then washed four times with ice-
cold PBS and incubated with ice-cold PBS containing the general
protease, Pronase (1 g dm−3), for 30 min at 4 ◦C to separate
internalised andmembrane-bound 59Fe.26 Cellswere removed from
the substratum using a plastic spatula in the Pronase solution and
centrifuged at 14000 × g for 1 min. The supernatant (membrane-
bound 59Fe) and pellet (internalised 59Fe) were then separated
using a Pasteur pipette and transferred to c-counting tubes for
the determination of radioactive 59Fe.
DNA plasmid degradation
The ability of the chelators to protect (or potentiate)DNAplasmid
degradation in the presence of FeII and H2O2 was examined
using published techniques.17 The chelators were incubated for
30 min in the presence of FeII (10 lmol dm−3), hydrogen peroxide
(1mmol dm−3) and plasmidDNA (10 lg cm−3) in the presence and
absence of chelators. Samples were then loaded onto a 1% agarose
gel and electrophoresed for 1 h at 90 V.17
Results and discussion
The HPCIH analogues: structure and properties
We previously published the crystal structures of the free ligands
HPCIH, HPCBH, HPCFH29 and HPCAH.19 Here we report
the additional crystal structures of HPCNH·2H2O, HPCPH,
HPC2BBH·2H2O and HPC3HH (Fig. 3).
The bond lengths and angles are as expected for compounds
of this type.29 In every case, the pyridyl N-atom was anti with
respect to the imine N-atom, which avoids repulsion between the
H-atoms attached to C4 and C6. As a consequence, the molecule
is unfavourably disposed to coordinate a metal ion through the
pyridyl N-atom (N1), imine N-atom (N2) and carbonyl O-atom
(O1). Most of the ligands, including HPCIH,29 are effectively
planar with N1–C5–C6–N2, C6–N2–N3–C7 and N3–C7–C8–C9
torsion angles close to 180◦. However, the 2-bromophenyl ring
in HPC2BBH is twisted about the C7–C8 bond, which may be
attributed to the steric effect of the ortho Br atom, forcing the ring
to rotate by a much greater extent than the other analogues.
The salts (H2PC3BBH)ClO4·2H2Oand (H2PC4BBH)ClO4·H2O
(Fig. 4) were crystallised from dilute perchloric acid solutions
(pH 2). The pyridyl N-atom (N1) is identified as the site of
protonation. Bond lengths and angles are not affected by the
protonation as expected, which remain comparable to the rest
of the ligands in the series. In contrast to HPC2BBH (Fig. 3),
the bromine atoms in (H2PC3BBH)+ and (H2PC4BBH)+ (Fig. 4)
no longer impose any steric influence on the conformation of
the phenyl ring and thus the molecules are virtually planar (N1–
C5–C6–N2 and N3–C7–C8–C9 torsion angles at 180◦ and 174.2◦
for (H2PC3BBH)+ and 175.1◦ and 168.4◦ for (H2PC4BBH)+,
respectively).
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Fig. 3 ORTEP drawings of the neutral hydrazones: HPCNH·2H2O, HPCPH, HPC2BBH·2H2O and HPC3HH (30% probability ellipsoids).
Fig. 4 View of [H2PC3BBH]ClO4·2H2O (left) and [H2PC4BBH]ClO4·H2O (right) (30% probability ellipsoids).
In contrast with the structures of the neutral hydrazones in
Fig. 3, the conformations of the protonated hydrazones are
quite different. The pyridyl and imine N-atoms are now syn
and the ligands are primed for tridentate coordination (Fig. 4).
Interestingly, a water molecule occupies the position normally
taken by a coordinated metal ion, H-bonds replacing coordinate
bonds in this instance. The water protons donate H-bonds to the
imine-N and carbonyl-O atoms, while the water O-atom accepts
an H-bond from the pyridinium NH group (Fig. 4).
Protonation constants
Charged chelators (at physiological pH 7.4) are hindered in their
passage across cellular membranes and cannot gain access to
intracellular Fe pools nor can they be absorbed from the gut.1,30
The protonation constants of the HPCIH series of ligands were
determined and the results appear in Table 2. The assignment of
pKa values of ionisable protons in theHPCIHanalogues conforms
to reports of similar aroylhydrazones.30–36 The first protonation
constant (pK1) is associated with the hydrazone N–NH–C=O
group, while the lower pKa value (pK2) is assigned to protonation
of the 2-pyridyl ring, which is supported by crystallographic
evidence reported here (Fig. 4).
A significant inductive effect by the non-coordinating aro-
matic substituent on pK1 is apparent. The electron-withdrawing
isonicotinoyl group accounts for the low pK1 value (9.17(1)
for HPCIH). Conversely, the electron-donating 4-aminobenzoyl
group accounts for the highest pK1 value (11.63(3) for HPCAH).
The value of pK1 is important in determining the amount
of ionised ligand at physiological pH (7.4) and also has a
bearing on the proton-independent formation constants19 (see
below). In summary, most of the HPCIH analogues will be
dominantly neutral at pH 7.4. Indeed, HPCTH as one of our
lead compounds has been shown to penetrate cells and induce
This journal is © The Royal Society of Chemistry 2007 Dalton Trans., 2007, 3232–3244 | 3237
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Table 2 Protonation constants and partition coefficients of the HPCIH
analogues
pK1 (amide-N) pK2 (2-pyridyl-N) log P (octanol–H2O)
HPCIH 9.17(1) 3.61(1) 1.98
HPCNH 9.34(3) 3.50(2) 1.94
HPCPH 9.56(4) 3.84(4) 2.32
HPCBH 9.78(1) 3.37(1) 2.84
HPCAH 11.63(3) 3.83(4) 2.31
HPC3AH 10.61(2) 3.49(1) 1.94
HPC4BBH 9.61(3) 3.80(4) 4.17
HPC3BBH 10.12(2) 3.28(2) 3.70
HPC2BBH 9.96(5) 3.32(3) 3.06
HPC4HH 9.38(4) 3.26(4) 2.78
HPC3HH 9.25(1) 3.21(1) 2.94
HPCTH 9.38(3) 4.15(2) 2.79
HPCFH 10.25(2) 3.18(1) 2.47
the release of intracellular Fe16 and is an orally-active Fe chelator
in mice.18
Fe complexes
The syntheses of FeII complexes of the HPCIH analogues in pure
form required carefully controlled conditions or else mixtures
of mono- and bis-ligand complexes were obtained. Ferrous
perchlorate was used as the salt, a large excess of triethylamine
(20 equivalents) was added and the solvent was MeCN. This
procedure was a successful general method to synthesise all FeL2
complexes from the HPCIH analogues. A notable exception was
HPCPH, where a partially oxidised di-FeII, triple helical Fe2(L2L′)
mixed ligand (hydrazone/hydrazine) complex was formed.37 The
peculiarities of this compound arise from participation of the
2-pyridyl N-donor adjacent to the carbonyl group.37 No Fe
complexes of this ligand are reported here.
Upon complexation of the HPCIH ligands, the IR vibrations
involving the –HN–C=O– (‘amide’) functional group of the
hydrazone ligands were most affected.38,39 The NH proton is lost
upon complexation and the amide group is converted to an enolate
form i.e. –N–C=O–Fe. The carbonyl stretching frequency seen in
the free ligands (1630–1700 cm−1) shifts to lower frequency. Given
the complexity of the IR spectra in the range 1200–1600 cm−1,
an unambiguous assignment is difficult due to overlapping C=C
and C=N vibrations from the aromatic rings. However, all Fe
complexes exhibit a strong IR absorption at ca. 1380 cm−1 which
was not observed in the free ligands and is probably due to the
–N=C–O–Fe moiety.
The electronic spectra of the FeII complexes of the HPCIH
series in methanol were similar and each featured an intense,
broad, asymmetric maximum at ca. 640 nm. By analogy with the
closely related low spin FeII complexes of the HPKIH analogues
(Fig. 2),36 this transition is most likely of metal-to-ligand charge-
transfer (MLCT) origin. All complexes exhibit intense ligand-
based transitions in the near UV region at ca. 350 nm and
280 nm. A bathochromic shift is observed in these ligand-based
transition bands as the aromatic substituent on the ligand becomes
more strongly electron-donating. HPCAH, which bears the most
strongly electron-donating substituents of the series, has the lowest
energy maxima at 381 nm and 332 nm.
The 1H NMR spectra of the FeII complexes measured in d6-
DMSO exhibited broad and downfield-shifted singlets for all
protons (regardless of their environment) in contrast to the
well resolved multiplets seen in the spectra of the free ligands.
This feature is due to paramagnetism arising from a high-
spin/low-spin equilibrium in solution. No time dependence in
the spectra was noted, so paramagnetic impurities from aerial
oxidation of the complex can be ruled out. The number of
peaks seen in each 1H NMR spectrum was always less than the
number of chemically distinct protons. The magnitude of the
paramagnetic shift is indicative of the amount of high spin FeII
present and this varied considerably across the series. A full and
accurate assignment of eachNMR spectrum, as performed for the
analogous Fe(PKIH)2 series,36 was not feasible but there are some
clear trends apparent across the series of twelve Fe complexes.
The non-coordinating aromatic/heterocyclic ring protons appear
least affected by paramagnetism and are seen in the range of 7–
10 ppm.The remaining peaks are considerably broader and appear
well downfield (> 10 ppm). These correspond to the 4 pyridyl
protons and the single azomethine proton. However, in no case
were all 5 peaks seen. The complexes Fe(PCNH)2, Fe(PC4AH)2
and Fe(PC3AH)2 each exhibited 4 of the 5 expected peaks from
the pyridine carbaldehyde moiety while all other complexes gave
only 3 resonances with a large downfield shift. In our previous
study with the Fe(PKIH)2 analogues,36 we showed that the proton
most affected by paramagnetism was that in the 6-position of the
coordinated pyridyl ring although in that case the paramagnetism
was only very mild by comparison. Extrapolating to this system,
we believe that the NMR resonance for the proton attached to
atom C1 in Fig. 2 and 3 of all complexes was never seen in our
NMR spectra due to an extremely large paramagnetic shift (and
broadening). Thus the most downfield shifted proton of the four
seen in the spectra of Fe(PCNH)2, Fe(PC4AH)2 and Fe(PC3AH)2
(the least paramagnetic compounds of this series) is presumably
from the azomethine proton, which like the proton adjacent to the
coordinated pyridyl N-atom is in closest proximity to the Fe ion
and subject to the greatest influence of its paramagnetism.
The complex [Fe(PC2BBH)2]·1/2EtOAc was successfully crys-
tallised from ethyl acetate and its crystal structure determined
at low temperature (150 K). The asymmetric unit comprises two
complex molecules and a single ethyl acetate solvent molecule.
Fig. 5 shows one complexmolecule from the asymmetric unit. This
bis-ligand complex is representative of the preferred bindingmode
of the HPCIH analogues and is the first bis-ligand Fe complex
structurally characterised from this series. The coordination about
FeII can be described as distorted octahedral, with the two
tridentate ligands arranged in a meridional fashion, orthogonal
to each other. The bite angles defined by the two consecutive
five-membered chelate rings of the coordinated hydrazone are
ca. 80◦, thus resulting in the distorted octahedral coordination
geometry. The bond lengths are characteristic of low spin FeII and
very similar to those reported for the related FeII complexes of the
HPKIH analogues.36
In the Fe(PC2BBH)2 complex, the 2-bromophenyl rings are
twisted away from the plane of the ligands by ca. 45◦ (Fig. 5),
similar to that seen in the structure of the free ligand (Fig. 3). The
two complexes within the asymmetric unit exhibit slightly different
conformations. In themolecule shown in Fig. 5, one bromine atom
(Br1B) is syn with respect to the carbonyl group, while the other
(Br1A) is anti, whereas in molecule 2 (not shown) both bromine
atoms are syn with respect to their adjacent carbonyl groups.
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Fig. 5 ORTEP drawing of one of the two independent Fe(PC2BBH)2
molecules (30%probability ellipsoids): selected bond lengths (A˚) Fe1–N1A
1.95(1), Fe1–N1B 1.94(1), Fe1–N2A1.86(1), Fe1–N2B 1.866(9), Fe1–O1A
1.987(8), Fe1–O1B, 1.979(8), C7A–N3A 1.32(2), C7B–N3B 1.35(2),
C7A–O1A 1.30(1), C7B–O1B 1.29(1).
Complex formation constants
The FeII complex formation constants of the HPCIH series (in
water) have been determined and are given in Table 3. Equilibrium
constants for the formation of both mono- ([FeL]+) and bis-ligand
(FeL2) complexes were calculated. Under the conditions of the
experiment, charge-neutral bis-ligand complexes of the typical
formula Fe(PCIH)2 are the prevailing species at physiological
pH of 7.4, while mono-ligand complexes [Fe(PCIH]+ begin to
form at pH ≈ 3. This is significant, as it means that a bis-ligand
FeII complex formed within the cell may freely permeate the cell
membrane to re-enter the plasma for excretion, since it carries no
charge.40 Hence, the neutral charge of the ligand and Fe complex
may explain, at least in part, the high Fe chelation efficacy of many
of these ligands, including HPCTH which has been examined in
vitro and in vivo.16,18
The pM scale (–log10[uncomplexed metal ion] at pH 7.4 after
equilibration of 1 lmol dm−3 metal ion and 10 lmol dm−3
ligand)41,42 allows comparison of the relative ability of different
ligands to bind a metal under comparable physiological con-
ditions. In simple terms, the pM value is calculated from the
proton-dependent stability constant, which is in turn derived
from the ligand protonation constants and complex formation
constants. The pM values for the formation of FeIII complexes of
transferrin,41,42 as well as FeII and FeIII complexes of DFO41–43 and
H2PIH44 are tabulated for comparison (Table 3). The variation in
pM values for the formation of FeII complexes is relatively small
across the HPCIH series. In fact, the small difference in affinity
for FeII among the HPCIH analogues is inadequate to account for
the difference in their biological activity (see below). This clearly
indicates that factors other than metal selectivity and affinity are
responsible for the diversity in Fe chelation efficacy within the
series and justify the assessment of factors such as lipophilicity, as
described below.
The HPCIH analogues possess higher affinity for FeII than
does DFO (pM = 6.13). On the other hand, the high affinity
of the hexadentate DFO for FeIII is rational, since it is a bacterial
siderophore “designed” to sequester FeIII specifically, coordinating
through six hard O-donors.45,46 In contrast, the HPCIH analogues
coordinate through the pyridyl-N, imine-N and carbonyl-O atoms,
furnishing a softer N4O2 coordination sphere which leads to a
preference for divalent over trivalent iron. Of note, the monobasic
HPCIH analogues form charge-neutral bis-ligand complexes with
divalent metal ions19 (including Fe here).
Electrochemistry
In pure MeCN solution the Fe(PCIH)2 analogue complexes
displayed two reversible redox responses. The redox potentials
are shown in Table 4 and a typical cyclic voltammogram of
Fe(PCFH)2) inMeCN, is illustrated in Fig. 6. The higher potential
voltammetric responses (E◦ ′ between −200 mV and 0 mV vs.
Fc+/0 (MeCN)) are assigned to the FeIII/II redox couple. The lower
potential responses (Table 4) fall within a rather narrow range
and their current magnitude is consistent with a net two electron
process by comparison with the obligate single electron high
potential (FeIII/II) couple. The only redox active moiety common
to the entire series (apart from the metal itself) is the coordinated
Table 3 Partition coefficients for Fe complexes of the HPCIH analogues, their proton-independent Fe complex formation constants and pM values.
Data for transferrin, DFO and H2PIH included for comparison
log P (octanol–H2O) log b1 log b2 pM (FeII) pM (FeIII)
Fe(PCIH)2 1.89 7.02(2) 13.37(2) 6.50 —
Fe(PCNH)2 1.85 7.12(4) 14.38(3) 6.67 —
Fe(PCBH)2 2.89 7.07(2) 13.81(2) 6.20 —
Fe(PC4AH)2 1.99 8.47(3) 17.58(3) 6.11 —
Fe(PC3AH)2 2.25 7.54(2) 14.92(2) 6.09 —
Fe(PC4BBH)2 2.67 7.00(8) 14.58(6) 6.43 —
Fe(PC3BBH)2 3.52 7.14(8) 14.93(3) 6.44 —
Fe(PC2BBH)2 3.01 6.93(5) 13.60(4) 6.10 —
Fe(PC4HH)2 2.67 6.37(3) 11.81(5) 6.10 —
Fe(PC3HH)2 2.60 6.43(1) 12.35(1) 6.15 —
Fe(PCTH)2 3.00 7.30(2) 14.18(4) 6.62 —
Fe(PCFH)2 2.20 7.56(2) 14.64(2) 6.20 —
Fe2-transferrin — — — — 25.6a
Fe(DFO) 6.13b 26.6b
Fe(HPIH)(PIH) 3.1c 7.14d 27.7d
a Ref. 41 and 42. b Recalculated frompublished proton independent stability constants (ref. 43). c Ref. 49. d Recalculated frompublished proton independent
stability constants (ref. 44).
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Table 4 Redox potentials of the FeII complexes of HPCIH series in 100%
MeCN and 50%DMF : H2O. All couples inMeCNwere totally reversible,
while in DMF : H2O only the anodic (FeII to FeIII) peak potential (Epa) is
listed due to total irreversibility of the response
MeCN (Eo′ vs. Fc+/0)/mV
50% DMF : H2O
(Epa vs. NHE)/mV
[FeL2]+/0 [FeL2]0/− [FeL2]+/0
FeII(PCIH)2 −11 −1585 616
FeII(PCNH)2 −53 −1647 593
FeII(PCBH)2 −105 −1697 531
FeII(PC4AH)2 −206 −1766 426
FeII(PC3AH)2 −133 −1711 520
FeII(PC4BBH)2 −80 −1677 543
FeII(PC3BBH)2 −66 −1633 544
FeII(PC2BBH)2 −67 −1674 542
FeII(PC4HH)2 −88 −1717 497
FeII(PC3HH)2 −107 not obs. 534
FeII(PCTH)2 −65 −1664 544
FeII(PCFH)2 −63 −1665 583
Fig. 6 Cyclic voltammogramofFe(PCFH)2 inMeCN.Direction of initial
sweep shown by arrow and the sweep rate was 100 mV s−1.
2-pyridyl ring. The two electron stoichiometry is indicative of
overlapping single electron reductions of the coordinated pyridyl
ligands i.e. there is no interaction between the two ligands and
their redox potentials are too close to be resolved. This is similar
behaviour to that reported in the electrochemistry of the related
Fe(PKIH)2 complexes.36 Of note, is the significantly more negative
potentials exhibited by Fe(PCAH)2. This is consistent with the
strong electron-donating effect of the 4-aminophenyl substituent
disfavouring both metal and ligand based reductions. At the other
end of the series, Fe(PCIH)2 displayed themost positive potentials,
in this case most likely due to the strongly electron-withdrawing
isonicotinoyl ring. A similar trend has been reported in the related
Fe(PKIH)2 series.36
Electrochemistry of Fe(PCIH)2 in a 1 : 1mixture ofDMF/water
was investigated to provide more physiologically relevant redox
potentials. Due to the limited aqueous solubility of the complexes,
a minimum of 50% DMF was required to keep all complexes in
solution and enable comparisons across the entire series. Due to
the narrower potential window offered by this solvent, only the
FeIII/II couple was investigated.
Fig. 7 illustrates the cyclic voltammogram of Fe(PCIH)2 in 1 :
1 DMF/water mixture at pH 7. All of the Fe(PCIH)2 analogues
displayed totally irreversible redox responses around 500 mV (vs.
NHE) at pH = 7 (Table 4) that are consistent with a chemical
reaction following oxidation (EC mechanism). Previously, we
discussed this mechanism in the related Fe(PKIH)2 analogues
Fig. 7 (left) Cyclic voltammogramofFe(PCIH)2 in 50%aqueousDMFat
pH 7 (sweep rate 100mV s−1) and (right) proposed ‘square’ electrochemical
scheme (only one coordinated ligand is shown for clarity but both are
assumed to undergo the same reaction simultaneously).
and modelled the electrochemistry using digital simulation.36,37
The proposed mechanism adapted to this system is also shown in
Fig. 7 (right). Briefly, in MeCN, only the reversible single electron
exchange between compounds A and B (top line) was relevant.
However, in the presence of water, the ferric complex undergoes
rapid nucleophilic attack by hydroxide to produce compound C.
The latter is reduced at a much lower potential (ca. 0 mV) to give
compound D. Compound D is also unstable and eliminates water
to restore the original FeII complex A in a process that may be
cycled indefinitely.
The electrochemistry of the other Fe(PCIH)2 analogues in the
same solvent was similar and in all cases a totally irreversible
FeIII/II couple was identified. The redox potentials followed the
same trend seen in the non-aqueous electrochemistry, indicating
that the inductive effects of the non-coordinating aromatic rings
are qualitatively similar in both water and MeCN. Due to the
irreversibility of the FeIII/II couple in DMF : water, only the anodic
peak potential is shown in Table 4. It is notable that the peak
positionwas sweep rate independent, thus the initial redox reaction
is associated with a rapid heterogeneous electron transfer.
These results are very interesting when compared with those
of the structurally similar Fe(PKIH)2 analogues, where the ferric
complexes underwent hydrolysis at a much slower rate (pseudo
first order rate constants 2–50 s−1)36 than the Fe(PCIH)2 analogues
observed here. At sweep rates of 1 V s−1 an appreciable cathodic
([FeIII(PKIH)2]+ to FeII(PKIH)2) wave was seen. Even at sweep
rates as high as 20 V s−1 no cathodic (FeIII to FeII) response in the
vicinity of the initial anodic peak around 500mV could be seen for
the Fe(PCIH)2 complexes. Thus, there was an order of magnitude
increase in the rate of attack on the ferric complexes of the
HPCIH analogues. The FeIII/II redox potentials of the Fe(PKIH)2
complexes36 are essentially the same as the corresponding couples
for the Fe(PCIH)2 analogues reported here. The only structural
difference is the replacement of the non-coordinating 2-pyridyl
group in the HPKIH analogues with an H-atom in the HPCIH
series. Indeed, it is the C-atom to which these groups are attached
that we propose is the target for nucleophilic attack by OH−
and evidently this reaction occurs much more slowly in the
HPKIH analogues. One obvious explanation is that the pyridyl
ring provides steric hindrance to nucleophilic attack (compared
with anH-atom). However, there could be an inductive effect from
the 2-pyridyl ring that lowers the electrophilicity of the attached
C-atom, but in the absence of other analogues bearing different
substituents at this position it is difficult to comment further.
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Partition coefficients
The rate of passive diffusion of a compound across biological
membrane and into cells will be a function of lipophilicity, con-
veniently quantified by its partition coefficient (log P) between 1-
octanol andwater.47 In previous studies on analogues ofH2PIH48,49
and deferiprone (L1) (Fig. 1),50 and also other Fe chelators,51 it was
observed that the relationship between Fe mobilisation activity
and log P of these compounds depends not only on the partition
coefficients of the ligands, but also on the partition coefficients
of their Fe complexes. In this study, the 1-octanol–water partition
coefficients of the HPCIH analogues and their FeII complexes,
respectively, were determined by published methods.52 In the case
of the Fe complex partition coefficients, all solutions were purged
with nitrogen and sealed to prevent FeII oxidation. The 1-octanol–
water partition coefficients of the HPCIH analogues and their FeII
complexes are given in Tables 2 and 3.
All of the HPCIH analogues have log P equal to or greater
than 2 (Table 2), with the two most lipophilic ligands of the
series, HPC3BBH and HPC4BBH, displaying log P values of
3.70 and 4.17, respectively. The FeII complexes of the HPCIH
analogues possess similar partition coefficients to their free ligands
(Table 3). The majority of the biologically active compounds
examined by Hansch et al. have maximum activity at values of
log P between 2 and 6.47,53 Compounds with high log P values
are sparingly soluble in aqueous media (and problematic in terms
of drug delivery) and thus a balance between hydrophobicity and
aqueous solubility needs to be found. Edward et al. reported that
the H2PIH analogues have maximum activity in releasing 59Fe
from reticulocytes when they have intermediate values of log P
[free ligand] ≈ 2.8 and log P [FeIII complex] ≈ 3.1.49,54 Most of the
HPCIH analogues have logP [free ligand] and logP [FeII complex]
values within this ‘optimal’ range.
Cellular Fe efflux and uptake experiments
The ability of the HPCIH analogues to gain access to intracellular
Fe is central to their potential use in the treatment of Fe overload.
To examine the efficacy of a chelator to deplete cellular Fe pools
we implemented establishedmethods, namely Fe efflux and uptake
experiments using SK-N-MC cells, to investigate this.7,25,52,55,56 The
Fe efflux studies (Fig. 8A) assess the ability of a chelator to
penetrate the cell membrane and bind and mobilize59 Fe from
intracellular Fe pools that have been pre-labelled by incubation
with 59Fe-Tf. This determines if a chelator can enter the cell and
leave with cellular 59Fe bound to it. We also examined the effects
of the PCIH analogues at preventing cellular 59Fe uptake from
59Fe-Tf (Fig. 8B). This latter property also necessitates membrane
permeability and examines the ability of the ligand to compete
with the cell for 59Fe released from 59Fe-Tf in the endosome. As
internal controls, we have also assessed the well characterised Fe
chelators, DFO and H2PIH (Fig. 1). All the results are compared
to control samples prepared in the absence of chelator.
As is evident from Fig. 8A, DFO showed only modest 59Fe
efflux activity (13% cellular 59Fe release) relative to the control
(7% cellular 59Fe release with no chelator), which was consistent
with our previous work.16,25,57 This low activity was due to the
hydrophilicity and low membrane permeability of DFO.7,57 In
contrast, H2PIH showed marked efficacy leading to the release
Fig. 8 The effect of DFO, H2PIH and the HPCIH analogues at
25 lmol dm−3 on: (A) 59Fe efflux from pre-labelled SK-N-MC neuroep-
ithelioma cells and (B) their ability to prevent 59Fe uptake from 59Fe-Tf by
SK-N-MC neuroepithelioma cells. Results in (A) are presented as 59Fe
efflux as a percentage of total cellular 59Fe, while the data in (B) are
expressed as a percentage relative to control with no chelator present (i.e.
100% uptake of 59Fe). Data are presented as the mean ± SD of 5 replicates
in a typical experiment of two separate experiments performed.
of 69% of cellular 59Fe which is ten-fold higher than the control
(Fig. 8A). In fact, H2PIH was the most effective chelator screened
in this investigation and its activity was comparable to that
observed in our previous studies.25,27
All chelators from the HPCIH series except those with
aminophenyl, hydroxyphenyl or furan substituents were signifi-
cantly (p < 0.01) more effective than DFO in releasing 59Fe from
prelabelled cells (Fig. 8A). No significant effects due to isomerism
in the analogues with bromophenyl, hydroxyphenyl, aminophenyl
and pyridyl groups in various positions were found. The most
effective analogues were HPCIH, HPCNH, HPCPH, HPCBH
and HPCTH.
The ability of the HPCIH analogues to inhibit cellular 59Fe
uptake from 59Fe-Tf is shown in Fig. 8B. Note that in this case, an
effective chelator will reduce uptake of 59Fe from 59Fe-Tf leading
to a marked decrease of intracellular 59Fe relative to the control
without chelator. In agreementwithprevious studies,DFOshowed
very little activity at inhibiting 59Fe uptake from Tf,7,57 while
H2PIH markedly reduced59 Fe uptake to 25% of the control. As
observed in the 59Fe mobilisation study (Fig. 8A), the HPCIH
analogues bearing amino, hydroxyl or furoyl substituents were
largely ineffective at preventing 59Fe uptake from 59Fe-Tf (Fig. 8B).
Chelators HPCBH, HPC2BBH, HPC3BBH, HPC4BBH and
HPCTH were the most effective ligands of the HPCIH analogues.
Indeed, the ligands showed efficacy comparable to H2PIH at
preventing 59Fe uptake from 59Fe-Tf to 26–31% of the control
(Fig. 8B).
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Considering these latter data showing that the best HPCIH
analogues have comparable activity to H2PIH at preventing
59Fe uptake, it is of interest that the ability of the HPCIH
analogues at inducing 59Fe mobilisation from cells was much less
than H2PIH (Fig. 8A). Indeed, the HPCIH ligands are more
effective at inhibiting 59Fe uptake from 59Fe-Tf than mobilising
intracellular 59Fe. After receptor-mediated endocytosis of diferric
transferrin (Fe-Tf), Fe is released within the endosome and
reduced to FeII where it is then transferred to the divalent cation
transporter (DCT1).1,4 This latter molecule transports FeII across
the membrane and into the cellular labile Fe pool.1,58 Then Fe
is either used for incorporation into proteins or stored within
ferritin. The fact that the HPCIH analogues are very successful
in preventing 59Fe-uptake, may reflect a kinetic effect whereby
Fe is intercepted by the chelators en route before it is stored.
In contrast, in cells prelabelled with 59Fe-Tf, both FeII and FeIII
exist intracellularly59 and the ability of the HPCIH analogues to
bind predominantly FeII may disadvantage their activity relative
to H2PIH which binds both redox states.44,60
In terms of the activity of the ligands in both 59Fe mobilization
and 59Fe uptake assays, the most effective HPCIH series chelators
were HPCBH and HPCTH which showed high activity in both
studies. On inspection of their physical properties (Table 2) and
those of their Fe complexes (Table 3), the intermediate log P
values coupled with favourable ionisation constants that lead to
charge neutral chelators and FeII complexes appears to be an
ideal combination for effective Fe chelation. On the other hand, it
appears that hydrophilic substituents such as amino or hydroxyl,
irrespective of their position on the phenyl ring, have a deleterious
effect on Fe binding efficacy as found for other aroylhydrazones.55
Hence, such groups as well as the furan substituent which also
led to poor Fe chelation efficacy, should be avoided in the future
design of ligands of this class.
DNA plasmid degradation
Upon complexation of intracellular Fe by a chelator, Fe may
be rendered redox active and promote Fenton chemistry where
FeII catalytically decomposes H2O2 to generate hydroxyl radicals
and other ROS.1 These ROS can cause adverse effects to normal
cellular function and proliferation.17,61 Alternatively, chelators
such as DFO can bind Fe and prevent Fenton chemistry.17
Hence, clearly the redox activity of the Fe complex is vital
to determine for assessing its use as a clinically effective agent.
The plasmid single and double strand-break assay was used to
determine the ability of the chelators to cause DNA strand breaks
through Fenton chemistry.17,62–65 A single strand break causes
conversion of supercoiled (SC) DNA into the open circular (OC)
form, while a double strand break results in the SC form being
converted to linear (L) DNA.
For simplicity, comparisons between all the HPCIH analogues
and controls were made based on the percentage of SC DNA
remaining after the assay and these data are summarised in
Fig. 9 and 10. A number of different controls were used in these
studies.17 These included, plasmid treated with the restriction
enzyme BamH1 which resulted in complete conversion to L DNA
i.e. 0% SC DNA (Fig. 9, lane 2); untreated plasmid (Fig. 9, lane 3)
and plasmid treated with hydrogen peroxide (Fig. 9, lane 4) that
appeared on gels as primarily the SC DNA band. When plasmid
Fig. 9 Typical plasmid FeII-mediated degradation assay of EDTA,
DFO and several HPCIH analogues (HPCNH, HPCPH, HPC3AH and
HPCAH). The HPCIH analogues at iron-binding equivalent (IBE) ratios
of 0.1, 1 and 3 were incubated for 30 min in the presence of FeII (10 lM),
hydrogen peroxide (1 mM) and plasmid DNA (10 lg mL−1). Samples were
loaded onto a 1% agarose gel and electrophoresed for 1 h at 90 V. Results
are from a typical experiment of a total of 3 performed.
Fig. 10 Densitometric analysis of plasmid FeII-mediated degradation
assay of EDTA, DFO and all the HPCIH analogues examined in this
study. The experimental procedure is the same as that described in Fig. 9.
Results are from a typical experiment of a total of 3 performed.
was treated with FeII and hydrogen peroxide (Fig. 9, lane 5), SC
DNA was partially converted to the OC form. We also examined
various Fe to chelator stoichiometries in our study. These are
represented here as so-called “iron binding equivalents” (IBE).17
An IBE of one indicates a stoichiometric ratio of Fe to ligand such
that the octahedral coordination sphere of Fe is satisfied (i.e. 1 Fe
atom to 2 tridentateHPCIH ligands, or 1 Fe atom to 1 hexadentate
DFO ligand etc).17 An IBE of 0.1 indicates only about 10% of Fe
will be complexed, while an IBE of 3 means that there will be an
excess of uncomplexed ligand and this will favour complexation
in the case where the formation constants are only modest (see
Table 3).
In the presence of both FeII and H2O2, both EDTA and DFO
were protective of SC DNA at IBE of 3 (Fig. 9; lanes 6 and
7, respectively), in agreement with previous work.17,66 However,
HPCNH, HPCPH, HPC3AH and HPCIH in the presence of FeII
and H2O2 stimulated plasmid degradation, leading to a marked
decrease in SCDNA as the IBE increased to 3 (Fig. 9; lanes 9–20).
Comparisons between all the PCIH analogues were then made
based on the %SC DNA remaining and the results of the gel
quantified by scanning densitometry (Fig. 10). Only results at
IBEs of 1 and 3 are shown, as the results at an IBE of 0.1
were all similar to FeII in the presence of H2O2. Of the HPCIH
analogues, HPC3HH was the most damaging in terms of plasmid
3242 | Dalton Trans., 2007, 3232–3244 This journal is © The Royal Society of Chemistry 2007
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degradation, there being no SC DNA remaining at IBEs of 1
and 3 (Fig. 10). Of the remaining analogues, HPCIH, HPC4BBH,
HPC4HH, and HPCTH all reduced SCDNA to zero at an IBE of
3. On the other hand, HPCBH, HPC3BBH and HPC2BBH were
far less damaging, with greater than 50% of SC DNA remaining
at an IBE of 1.
These results were consistent with an earlier DNA degradation
study of a smaller subset of the HPCIH analogues.17 Single or
double strand breaks in naked plasmid in this assay were due to
Fe-catalysed redox activity and require the complex to be stable
in both the divalent and trivalent forms. The ferrous complex of
DFO is only formed at very low potential, and as such, it does
not participate in Fenton chemistry.67 Consequently, it shows no
significant plasmid degradation activity.17
However, redox activity does not necessarily mean that DNA
plasmid degradation is inevitable.17,36 Redox-active Fe com-
plexes that are negatively charged such as [Fe(EDTA)]2− are
repelled by like-charged DNA and show no significant plas-
mid degradation.17,36 All of the Fe(PCIH)2 analogues degrade
naked plasmid to some degree. Interestingly, the most damaging
complexes result from ligands that possess potentially H-bond
donating substituents (–OH, NH2; Fig. 10). Ironically, these were
also the least active at either mobilising intracellular 59Fe (Fig. 8A)
or inhibiting 59Fe uptake from 59Fe-Tf (Fig. 8B). We suggest that
these potential H-bond donors promote association of the Fe
complex with nucleic acid acceptor sites (phosphate, sugar etc.),
whereas the analogues with themore hydrophobic groups (phenyl,
bromophenyl) do not have a particularly great affinity for DNA.
In terms of the physiological significance of these results, it is
important to note that the ability of an Fe-complexed chelator to
degrade naked plasmid is only relevant if the complex can enter
the nucleus. Previously, we showed17 that although some of the
Fe complexes of the HPCIH analogues were capable of degrading
naked plasmidDNA in vitro, the damage to nuclear DNA in intact
human cells was insignificant. This suggests that the Fe(PCIH)2
complexes formed intracellularly do not gain access to DNA in
the nuclear compartment.
Conclusions
This investigation represents the first systematic study of the
FeII coordination chemistry of the HPCIH analogues. This work
was crucial, as this class of chelator shows great promise as an
orally effective drug for the treatment of Fe overload disease.16,18
A number of important conclusions can be drawn from these
experiments. First, unlike most other ligands that have advanced
to clinical trials such as DFO, L1 and ICL670A (Fig. 1), the
HPCIH analogues are FeII chelators.
Iron complexes of synthetic chelators may generate potentially
cytotoxic free radicals3 if they participate in redox cycling between
the di- and trivalent oxidation states. The aqueous voltammetry of
the Fe(PCIH)2 analogues although formally irreversible, involves a
reversible chemical reaction (hydration). In any case, the potential
at which the Fe(PCIH)2 analogues are oxidised (ca. 500 mV vs.
NHE) means that oxidation to the FeIII state by oxygen will be
very slow under physiological conditions. In the presence of strong
oxidants such as H2O2, oxidation could be more rapid and Fenton
chemistrymay result. However, whether this leads to nuclearDNA
damage or not is debatable and our results so far suggest that the
HPCIH analogues are relatively benign and are well tolerated in
vitro in cell culture16,17 and in vivo in mice.18
The HPCIH analogues show preference for FeII, forming low-
spin bis-ligand FeII complexes with pM values ranging from
6.1 to 7.1. The variation across the series is relatively small,
despite the difference in electronic effect of the distal substituents,
ranging from strongly electron-withdrawing, as in the case of
the isonicotinoyl group, to strongly electron-donating, as in the
case of the 4-aminobenzoyl ring. Also, their FeII pM values are
comparable to the existing drugDFO43 and thewidely investigated
H2PIH.30,44
The high FeIII/II redox potentials and instability of the ensuing
FeIII complexes effectively rule out compounds of the formula
[Fe(PCIH)2]+ as playing any significant role in a biological context.
This means that the HPCIH analogues are incapable of directly
competing with Tf for FeIII, whereas DFO is competitive for
trivalent Fe.55 Indeed, the ability of the HPCIH series to prevent
Fe uptake from Tf by cells can probably be explained by these
chelators acting after Fe release from Tf within the cell.58 The
in vitro Fe chelation efficacy of the HPCIH series established in
this study is probably attributed to their preference for chelating
intracellular FeII. It is well known that Tf-bound FeIII bound to
the transferrin receptor 1 is internalised by receptor-mediated
endocytosis.4 Within the endosome, FeIII is reduced to FeII and
then subsequently transported into the cell by DCT1.4 This Fe can
be used by metabolic processes and incorporation into the iron
storage protein, ferritin.58 Our uptake experiments demonstrate
that this FeII in transit can be intercepted by theHPCIHanalogues.
Considering the Fe chelation efficacy of the HPCIH series at
both inducing Fe efflux from pre-labelled cells and preventing
Fe uptake from Tf, the most active chelators were HPCBH and
HPCTH. The reasons for this high activity relative to the other
HPCIH chelators may be related to an optimal lipophilic balance
between the ligand and Fe complex. Certainly, in the current
study, it was clear that highly hydrophilic substituents such as
the amino and hydroxyl group did not confer high activity and
resulted in compoundswhich coulddegradeDNA.Hence, in terms
of structure–activity relationships, these latter groups should be
avoided in the design of future ligands.
In summary, the HPCIH analogues are an emerging class of Fe
chelators that have already been found to be orally-active and well
tolerated in a mouse model.18 The present study has shown that
these ligands are specifically FeII chelators (not FeIII). Considering
this, rather than competing with other more effective FeIII binding
proteins such as Tf, the HPCIH analogues must target divalent
Fe within the cell e.g. the labile Fe pool. The more hydrophobic
chelators of the series are most effective in terms of their ability
to mobilise 59Fe from 59Fe-loaded cells and to prevent cellular
uptake from 59Fe-Tf. It is also these lipophilic analogues that
show the least activity in degrading plasmid DNA, which is also
an important property of a clinically effective chelator for the
treatment of Fe overload disease.
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